Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B‐ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B‐cell lymphoma

There have been several attempts to improve treatment and outcome of patients with primary mediastinal B-cell lymphoma (PMBL) and Burkitt's lymphoma (BL). In recent years, chemotherapy dose intensification and the addition of rituximab have led to a remarkable progress and have developed into integral parts of treatment for both entities of lymphoma [1–4]. Here, we report our monocenter results of a high-dose methotrexate based alternating regimen with rituximab (B-ALL/NHL 2002 protocol) in 15 patients with PMBL and 28 patients with sporadic BL. Since the early 1980s, protocols of GMALL have been continuously adapted and in the meantime they have become reference treatment for BL and B-ALL in Germany. The latest changes comprised the additional use of rituximab, standardized G-CSF support,implementation of high-dose cytarabine, intrathecal triple therapy,and age-adjusted stratification. Furthermore, we additionally amended supportive care with palifermin as it reduced severity and prevalence of mucositis [5].

[1]  A. Carbone,et al.  Coexisting follicular and mantle cell lymphoma with each having an in situ component. , 2011, American journal of clinical pathology.

[2]  K. Mitani,et al.  In Situ Follicular Lymphoma Associated With Progressive Transformation of Germinal Centers , 2011, International journal of surgical pathology.

[3]  A. Carbone,et al.  Intrafollicular neoplasia/“in situ” lymphoma: A proposal for morphology and immunodiagnostic classification , 2011, American journal of hematology.

[4]  A. Santoro,et al.  How I treat: diagnosing and managing "in situ" lymphoma. , 2011, Blood.

[5]  M. Pfreundschuh,et al.  Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[7]  D. Ribatti,et al.  HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients , 2011, Leukemia.

[8]  R. Hebbel.  Reconstructing sickle cell disease: A data‐based analysis of the “hyperhemolysis paradigm” for pulmonary hypertension from the perspective of evidence‐based medicine , 2011, American journal of hematology.

[9]  H. Kantarjian,et al.  Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab , 2010 .

[10]  A. Rosta,et al.  Excellent Results In the Treatment of Primary Mediastinal Lymphomas , 2010 .

[11]  E. Vichinsky,et al.  The Effect of Thalassemia and Other RBC Hemolytic Disorders and Splenectomy on the Frequency of Pulmonary Hypertension , 2010 .

[12]  J. Byrd,et al.  Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002 , 2010 .

[13]  S. Kavanagh,et al.  Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. , 2010, The journal of pain : official journal of the American Pain Society.

[14]  G. Buchanan,et al.  Traditional laboratory measures of cardiovascular risk in hereditary spherocytosis , 2010, Pediatric blood & cancer.

[15]  O. Platt,et al.  Pulmonary hypertension and nitric oxide depletion in sickle cell disease. , 2010, Blood.

[16]  P. Veit-Haibach,et al.  Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Scott E. Smith,et al.  Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt's lymphoma (BL): Preliminary results of a multicenter phase II study. , 2010 .

[18]  Saraswati Sukumar,et al.  The Hox genes and their roles in oncogenesis , 2010, Nature Reviews Cancer.

[19]  C. Bach,et al.  Leukemogenic transformation by HOXA cluster genes. , 2010, Blood.

[20]  Juan F. García,et al.  Intrafollicular neoplasia/in situ follicular lymphoma: review of a series of 13 cases , 2010, Histopathology.

[21]  G. Morgan,et al.  Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome , 2010, Clinical Cancer Research.

[22]  A. Mottok,et al.  Double-staining chromogenic in situ hybridization as a useful alternative to split-signal fluorescence in situ hybridization in lymphoma diagnostics , 2010, Haematologica.

[23]  G. Buchanan,et al.  Vascular complications after splenectomy for hematologic disorders. , 2009, Blood.

[24]  A. Rossi,et al.  Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. , 2009, Clinical lymphoma & myeloma.

[25]  A. LaCasce,et al.  Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. , 2009, Clinical lymphoma & myeloma.

[26]  A. Neri,et al.  A SNP microarray and FISH‐based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect , 2009, Genes, chromosomes & cancer.

[27]  R. Halkar,et al.  Spectrum of FDG PET/CT Findings in Burkitt Lymphoma , 2009, Clinical nuclear medicine.

[28]  S. Swerdlow,et al.  Follicular lymphoma of the spleen: multiparameter analysis of 16 cases. , 2009, American journal of clinical pathology.

[29]  E. Thiel,et al.  Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate , 2009, Annals of Hematology.

[30]  E. Lonn,et al.  Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism , 2009, Internal and emergency medicine.

[31]  K. Imrie,et al.  In situ localization of follicular lymphoma: evidence for subclinical systemic disease with detection of an identical BCL-2/IGH fusion gene in blood and lymph node , 2009, Leukemia.

[32]  F. Costa,et al.  Newer Aspects of the Pathophysiology of Sickle Cell Disease Vaso-Occlusion , 2009, Hemoglobin.

[33]  A. LaCasce,et al.  Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive Burkitt Lymphoma , 2008 .

[34]  S. Barrans,et al.  A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). , 2008, Blood.

[35]  R. Gangnon,et al.  Delayed adverse vascular events after splenectomy in hereditary spherocytosis , 2008, Journal of thrombosis and haemostasis : JTH.

[36]  Gabor Grothendieck,et al.  Lattice: Multivariate Data Visualization with R , 2008 .

[37]  W. Berdel,et al.  Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  W. Hiddemann,et al.  High Survival Rate in Adult Burkitt’s Lymphoma/Leukemia and Diffuse Large B-Cell Lymphoma with Mediastinal Involvement. , 2007 .

[39]  B. Biemond,et al.  Patient‐controlled analgesia versus continuous infusion of morphine during vaso‐occlusive crisis in sickle cell disease, a randomized controlled trial , 2007, American journal of hematology.

[40]  W. Sanger,et al.  In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach. , 2007, Experimental and molecular pathology.

[41]  Robert H Christenson,et al.  National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. , 2007, Circulation.

[42]  J. McMurray,et al.  An epidemiological study of pulmonary arterial hypertension , 2007, European Respiratory Journal.

[43]  Rafael Fonseca,et al.  Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.

[44]  J. Smedema,et al.  Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis. , 2007, Cardiovascular journal of Africa.

[45]  L. Staudt.  A closer look at follicular lymphoma. , 2007, The New England journal of medicine.

[46]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  B. Lopez,et al.  Clinically Significant Differences in the Visual Analog Pain Scale in Acute Vasoocclusive Sickle Cell Crisis , 2007, Hemoglobin.

[48]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[49]  P. Korkolopoulou,et al.  Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL). , 2006 .

[50]  R. Owen,et al.  CNS prophylaxis in lymphoma: who to target and what therapy to use. , 2006, Blood reviews.

[51]  N. Schmitz,et al.  Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[53]  M. Cappellini,et al.  Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran , 2006, Thrombosis and Haemostasis.

[54]  E. Vichinsky,et al.  Pulmonary hypertension in thalassemia: Association with platelet activation and hypercoagulable state , 2006, American journal of hematology.

[55]  C. Denton,et al.  Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.

[56]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[57]  A. Phrommintikul,et al.  Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia , 2006, Heart.

[58]  H. Kantarjian,et al.  Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.

[59]  L. Staudt,et al.  Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation. , 2005 .

[60]  E. Cassinerio,et al.  Coagulation and Splenectomy: An Overview , 2005, Annals of the New York Academy of Sciences.

[61]  Cage S. Johnson,et al.  Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients , 2005, Medicine.

[62]  S. Bicciato,et al.  Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Humbert,et al.  Splenectomy and chronic thromboembolic pulmonary hypertension , 2005, Thorax.

[64]  M. Schemper,et al.  Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension , 2005, Thrombosis and Haemostasis.

[65]  Horst Olschewski,et al.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.

[66]  D. Hanna,et al.  Reliability and Validity of the Perioperative Opioid-Related Symptom Distress Scale , 2004, Anesthesia and analgesia.

[67]  J. Krishnan,et al.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[68]  H. Johnsen,et al.  Expression of HOXA Genes in Patients with Multiple Myeloma , 2004, Leukemia & lymphoma.

[69]  Edward J. Lee,et al.  Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma , 2004, Cancer.

[70]  D. Jardine,et al.  Delayed pulmonary hypertension following splenectomy for congenital spherocytosis , 2004, Internal medicine journal.

[71]  M. Paulli,et al.  Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B , 2004, British Journal of Cancer.

[72]  A. Holmes,et al.  Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2003, Respiratory medicine.

[73]  Paul Telfer,et al.  Guidelines for the management of the acute painful crisis in sickle cell disease , 2003, British journal of haematology.

[74]  E. Torlakovic,et al.  Follicular colonization by follicular lymphoma. , 2002, Archives of pathology & laboratory medicine.

[75]  E. Jaffe,et al.  In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. , 2002, Blood.

[76]  W. Wilson,et al.  CNS involvement in primary mediastinal large B-cell lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  H. Kantarjian,et al.  Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[79]  P. Flemming,et al.  Pulmonary Hypertension after Splenectomy? , 1999, Annals of Internal Medicine.

[80]  M. Kachoyeanos,et al.  A comparison of two regimens of patient-controlled analgesia for children with sickle cell disease. , 1998, Journal of pediatric nursing.

[81]  RoyG. Smith,et al.  Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: A case report and review of the literature , 1998, American journal of hematology.

[82]  J. K. Mcneely,et al.  Comparison of patient-controlled analgesia with and without nighttime morphine infusion following lower extremity surgery in children. , 1997, Journal of pain and symptom management.

[83]  C. Gisselbrecht,et al.  Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  G. Stewart,et al.  THROMBO‐EMBOLIC DISEASE AFTER SPLENECTOMY FOR HEREDITARY STOMATOCYTOSIS , 1996, British journal of haematology.

[85]  N. Morton,et al.  Comparison of patient-controlled analgesia with and without a background infusion after lower abdominal surgery in children. , 1993, British journal of anaesthesia.

[86]  P. Yock,et al.  Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. , 1984, Circulation.

[87]  J. Stockman,et al.  A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease , 2013 .

[88]  Elaina E. Lin,et al.  The effect of intravenous opioid patient-controlled analgesia with and without background infusion on respiratory depression: a meta-analysis. , 2010, Journal of opioid management.

[89]  T. Coates,et al.  Analgesic Response to Morphine in Children with Sickle Cell Disease: A Pilot Study. , 2008, Journal of pain management.

[90]  L. Horstman,et al.  Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. , 2008, Thrombosis research.

[91]  R. Gascoyne,et al.  Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  F. Di Serio,et al.  Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010 , 2005, Clinical chemistry and laboratory medicine.

[93]  M. Gladwin,et al.  Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. , 2005, Hematology. American Society of Hematology. Education Program.

[94]  Rajesh V Lalla,et al.  Oral mucositis. , 2005, Dental clinics of North America.

[95]  T. Molina,et al.  Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  M. Gossop,et al.  The development of a Short Opiate Withdrawal Scale (SOWS). , 1990, Addictive behaviors.

[97]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.